Jynarque is used to slow down the decline in kidney function in adults who have autosomal dominant polycystic kidney disease. Samsca boosts urine flow without creating the body to lose excessive salt as you pee. Tolvaptan may also be used for purposes not listed in this medicine overview. You additionally need to not use Jynarque if you have ever before had liver problems, or if your sodium blood degree is too low or too high. You might take tolvaptan with or without food. Long-lasting use of Samsca can damage your liver. Tolvaptan is -4'- [carbonyl] -otolu-mtoluidide. The empirical formula is C26H25ClN2O3. Molecular weight is 448. 94. The chemical framework is: Inactive components consist of corn starch, hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and FD&C Blue No. 2 Aluminum Lake as colorant. Tolvaptan is also used to slow down kidney function decline in adults that go to risk of quickly progressing autosomal leading polycystic kidney disease. Sodium is a chemical that the body requires for it to function well. If you have a low salt blood level, your body will not function normally and you may not really feel well. Tolvaptan operates in the kidneys to help maintain the right amount of sodium for the body. Samsca is offered only with your medical professional's prescription. Jynarque is offered only under a limited circulation program called the Jynarque REMS Program.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
https://www.drugs.com/mtm/tolvaptan.html
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebae8c22-2abf-4b81-9bab-e068e798a...
https://www.mayoclinic.org/drugs-supplements/tolvaptan-oral-route/description/drg-20073109
CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
216237 | C26H25ClN2O3 | 448.9 | CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C | CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C | InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31) | GYHCTFXIZSNGJT-UHFFFAOYSA-N | N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide | 4.8 | 448.1553704 | 448.1553704 | 69.6 | 674 | 0 | 2 | 3 | 3 | 32 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.
Contact
General contact: [email protected]